Sign Up | Log In | What is SocialPicks?

Investment Ideas Served Daily By People You Trust

SocialPicks is a community where stock investors exchange ideas and track performance of financial bloggers.

Are you a stock guru?

Share picks & earn reputation

Mike Havrilla www.ProActiveNewsRoom.com

Start Tracking Mike Havrilla - Add to Friends - Send Message

Community Rank: Principal (7000 pts) | Member since 07/15/2008

Picks Performance:

Outperforms

73%

of community

What's this?

All-time Return +1.04% (in 1 year)	Risk (SD) Conservative 0.00%	Sharpe Ratio -2.09
Followers 68	Winning Picks 786 of 1807	Total Views 929029

Overview

Stocks

Stats

Community

Widget

Mike Havrilla's Blog Posts

Visit Blog: ETF Innovators, LLP

MM ONTY Oncothyreon (ONTY) Research Note 03/18/09 — Visit the BioMedReports.com research section to view or download the PDF for Cougar Biotechnology (CGRB) along with other free PDF reports and corporate investor presentations:http://biomedreports.com/research.htmlOncothyreon (ONTY): Price: $1.21; Market Cap (MM): $23.6Market Outperform; Target Price...

Read 1 comment

MM CGRB Cougar Biotech Research Note 03/17/09 — Visit the BioMedReports.com research section to view or download the PDF for Cougar Biotechnology (CGRB) along with other free PDF reports and corporate investor presentations:http://biomedreports.com/research.htmlCGRB: Price: $28.46; Market Cap (MM): $590.1Market Outperform; Target Price: $36.00Simo...

Read 0 comments

DRRX UTHR Updated Clinical Trial and FDA Calendars 03/17/09 — Below is a summary of updates to the www.BioMedReports.com database of 243 entries included in the FDA and Clinical Trial Calendars.http://biomedreports.com/fda-calendar.html The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FD...

Read 0 comments

MM SNTA Synta Pharma Proceeds with Clinical Trial 03/17/09 — Visit the BioMedReports.com research section to view or download the PDF for Synta Pharma (SNTA) along with other free PDF reports and presentations:http://biomedreports.com/research.htmlSynta Pharma: Price: $1.94; Market Cap (MM): $65.8Market Perform; Simos Simeonidis, Ph.D. - Senior Biotech Analyst...

Read 0 comments

MM PARD Poniard Pharma Awaits Key Cancer Drug Data 03/17/09 — Visit the BioMedReports.com research section to view or download the six page PDF for Poniard Pharma (PARD) along with other free PDF reports and presentations:http://biomedreports.com/research.htmlPARD: Price: $1.87; Market Cap (MM): $64.9Market Outperform; Target Price: $10.00Simos Simeonidis, Ph.D...

Read 0 comments

ZIXI UNH ZixCorp: Close to Securing Profits 03/17/09 — Zix Corp. (ZIXI) is a component in the ETF Innovators Global Health IT Index which offers email encryption and electronic prescribing (e-prescribing) solutions, with the latter poised to experience significant growth thanks to a Medicare incentive program that started this year to encourage prescribe...

Read 0 comments

BioMedReports.com: Contributing Authors Wanted 03/16/09 — We are looking for contributing authors to submit articles for publication at BioMedReports.com; so if you are interested please contact me or use the online article submission link below:http://biomedreports.com/articles/contribute-an-article.htmlCurrently, there is no monetary compensation for arti...

Read 0 comments

Electro-Optical Sciences: Enabling Early Melanoma Detection 03/16/09 — MELA recently announced positive topline results in a pivotal clinical trial for MelaFind, which was conducted at seven medical centers across the U.S. and included nearly 1,400 patients and over 1,800 pigmented skin lesions. A larger study will also be conducted for MelaFind, with the results planne...

Read 0 comments

IV BAX Javelin Pharma: Late-Stage Pipeline Targets Pain 03/15/09 — Javelin Pharma (JAV) is focused on the late stage clinical development of three Phase 3 compounds while seeking partnerships for a non-dilutive source of funding. In mid-January, JAV established a partnership for Dyloject (injectable diclofenac) with Therabel Pharma to market the drug in Europe, wher...

Read 0 comments

NVS ILE Updated Clinical Trial and FDA Calendars 03/15/09 — Below is a summary of updates to the www.BioMedReports.com database of 242 entries included in the FDA and Clinical Trial Calendars. The two web links below are for the FDA calendar home page and a recent article highlighting 14 extreme trades of companies with market caps below $200M with pending FD...

Read 0 comments

CYTX JNJ Cytori Therapeutics: Stock Profile and 2009 Outlook 03/14/09 — Cytori Therapeutics (CYTX) is a leading global innovator in the emerging field of regenerative medicine using adipose (fat) tissue as a rich source of adult stem cells capable of differentiating into a variety of cell types. The Company develops and markets cell banking, therapeutic, and cosmetic med...

Read 0 comments

MM SNTA Research Note on Synta Pharma (SNTA) 03/13/09 — Synta Pharma (SNTA): Price: $1.97; Market Cap (MM): $66.8Market Perform; Simos Simeonidis, Ph.D.Senior Biotechnology Analyst http://biomedreports.com/research.htmlSynta cuts 42% of workforce; waiting for strategic alternatives guidanceThe News: Synta announced today a 42% reduction in its workforce, ...

Read 0 comments

CTIC MNTA Opinion: Pathway for FOBs Should Balance Need for Competition and Need for Innovation 03/12/09 — This story was written by James Bianco, M.D., prinicipal founder, CEO, and director of Cell Therapeutics (CTIC), which is a member of the ETF Innovators Emerging Bio-Pharma Index:http://biomedreports.com/health-indexes.htmlRelated Article on Momenta Pharma (MNTA) by Mike Havrilla:http://biomedreports...

Read 0 comments

DNA CCA Full Array of Reasons to Buy CombiMatrix 03/12/09 — CombiMatrix (CBMX) is an ETF Innovators Emerging Diagnostics Index component and spin-off company from Acacia Research (ACTG) which has operated independently since August 2007 as a developer of DNA MicroArrays for lab-based personalized medicine applications to improve treatment outcomes, which are ...

Read 0 comments

AMAG NVS Three Oversold Healthcare Catalyst Stocks 03/12/09 — With the S&P 500 SPDR ETF (SPY) trading about 8% below its 50-day moving average (DMA), I went in search of oversold healthcare stocks trading at least 16% below their 50 DMA which have potential catalysts within the next six months that may provide some very nice returns.The Healthcare Sector SP...

Read 0 comments

BDSI FDA and Clinical Trial Calendars at BioMedReports.com 03/11/09 — The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA deadline dates. The entries are updated on a daily basis as new information becomes available with a total of 102 entries as of 3/9/09. The FDA Calenda...

Read 0 comments

NVS MNTA Biotech Competition Legislation Introduced 03/11/09 — NORTH WALES, Pa., March 11, 2009 /PRNewswire-USNewswire via COMTEX/ -- Teva Pharma (TEVA), the leading generic pharmaceutical company, today applauded the introduction of a landmark, bi-partisan bill that would bring safe and affordable generic biologics to all Americans.Energy and Commerce Chairman ...

Read 0 comments

DDSS CTIC Trading FDA Decisions: 14 Extreme Trades 03/11/09 — Below is a summary of companies from the BioMedReports.com FDA Decision Date Calendar which have market caps below $200M, making them ideal candidates for extreme stock price volatility trades as their decision dates become imminent.Dyax Corp. (DYAX) secured a narrow approval from a FDA Advisory Pane...

Read 0 comments

ILE XLV Stem Cell Index Soars on Lift of Funding Ban 03/10/09 — The accompanying table includes statistics for the 40 companies in the ETF Innovators Global Stem Cell and Regenerative Medicine Index, which is down 14.2% at a value of 3,387 from a 2/22/09 inception date value of 3,928. Most of the stocks got a major boost today from the widely anticipated executiv...

Read 0 comments

DNA BMY Upcoming FDA Advisory Panel Meetings 03/09/09 — A trio of diabetes drug candidates are affected by a tougher stance at the FDA for this class of drugs, which is focused on cardiovascular risks such as heart attack and stroke. Two of the drugs will be reviewed at early April FDA advisory panel meeting while a third will likely require additional cl...

Read 0 comments

« previous
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
next »

More about Mike Havrilla

Investment Style:
Moderate [?]

Avg exp holding time:
85.39 days

Age: 30's	Occupation: Online Media Entrepreneur
Location: USA

Website:
www.ProActiveNewsRoom.com

About Me:

Mike Havrilla is an index developer, pharmacist, writer, and Co-Founder of BioMedReports.com with ex ... more

IN THE PRESS

None of the information contained on SocialPicks.com constitutes a recommendation by SocialPicks or its users that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person. SocialPicks is not responsible for the posts, discussions, and recommendations of the users on the Site. SocialPicks does not provide investment advice. You must make your own independent decisions regarding any security, portfolio of securities, transaction, or investment strategy mentioned on the website. SocialPicks' users' past results are not necessarily indicative of future performance. Neither SocialPicks nor any of its users guarantees any specific outcome or profit, and you should be aware of the real risk of loss in following any strategy or investments discussed on the website. You understand and agree that you use the Site and Services at your own discretion and risk and that you will be solely responsible for any damages that arise from such use. Before acting on any information contained on the website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.